Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

What do Oprah, Meghan Trainor, Kathy Bates, Fat Joe, Lizzo and Serena Williams all have in common? Their outspoken use of a glp-1 agonist to aid in weight loss and the improvement of other health ...

Like semaglutide, the new drug known as ecnoglutide is glucagon-like peptide-1 receptor agonist. In simple terms, they both ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

Dentists claim weight-loss drugs could majorly impact users' saliva glands, helping gum disease to fester in their mouths.

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Galectin's belapectin shows promise in MASH cirrhosis despite setbacks. High-risk investment with upcoming FDA meeting ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...